Loading clinical trials...
Loading clinical trials...
TRANSFORM: A 24-week, Randomized, Placebo-controlled, Double-blind, Phase 2b Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
Conditions
Interventions
Setanaxib
Placebo
Locations
128
United States
UA Thomas D. Boyer Liver Institute
Tucson, Arizona, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
California Liver Research Institute
Pasadena, California, United States
University of California Davis Medical Center
Sacramento, California, United States
Gastroenterology Associates - Crystal River
Inverness, Florida, United States
University of Miami Leonard M. Miller School of Medicine
Miami, Florida, United States
Start Date
February 14, 2022
Primary Completion Date
May 31, 2024
Completion Date
July 2, 2024
Last Updated
April 24, 2025
NCT07304843
NCT07449793
NCT05749822
NCT05751967
NCT06755541
NCT07296458
Lead Sponsor
Calliditas Therapeutics Suisse SA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions